FDA clears Appili Therapeutics to expand its trial of favipiravir for prrevention of Covid-19

Appili Therapeutics, a biopharmaceutical company focused on anti-infective drug development, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company clearance to proceed after Appili’s filing of an investigational new drug (IND) application for broad-spectrum antiviral favipiravir.